News
Shares of Novo Nordisk plunge 15% after Wegovy-maker cuts full-year guidance
Danish pharmaceutical giant Novo Nordisk on Tuesday cuts its full-year sales and profit guidance, citing weaker growth expectations for its Wegovy obesity drug in the key U.S. market. Shares were down 15% at 12:11 p.m. London time, shortly after the announcement.
San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...
A U.S. ban on copycat versions of Novo Nordisk's Wegovy has begun to lift use of the weight loss drug, but the company will need to show more robust growth in the months ahead to bolster market ...
While Novo Nordisk blamed rival drugs and its own tepid expansion for downgrades to sales and profit growth, some analysts ...
Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...
Pedersen, Stine Jacobsen and Maggie Fick COPENHAGEN (Reuters) -Investors wiped $70 billion off Novo Nordisk's market value on ...
The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.
GoodRx reports on identifying real Wegovy pens, which come in five colors and lack dose selectors. Counterfeits pose health ...
Wegovy is designed to be taken once a week by self-injection. Patients start on the lowest dose, 0.25 milligrams, and move up to the maintenance dose, 2.4 milligrams, over the course of 16 weeks.
Some patients reluctantly shifted to save money while others have appealed for coverage of Zepbound after having experienced ...
Novo Nordisk's new CEO Maziar Mike Doustdar has been handed the reins to turn around the Wegovy-making firm's flagging sales ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback